^
Association details:
| Biomarker: | ATP1B1-NRG1 fusion |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma
Excerpt:
Following progression on gemcitabine, patient 45 obtained access to afatinib….After 4 weeks, a repeat PET/CT was performed demonstrating a significant response to therapy….He had a CT at 3 months after treatment initiation confirming ongoing response.
DOI:
10.1158/1078-0432.CCR-19-0191
